Section Arrow
ONCY.NASDAQ
- Oncolytics Biotech
(Financial Status)
Quotes are at least 15-min delayed:2026/08/31 16:46 EDT
After Hours
Last
 0.8311
-0.0071 (-0.85%)
Bid
0.831
Ask
0.8429
High 0.8382 
Low 0.8311 
Volume 50 
Regular Hours (Closed)
Last
 0.8382
-0.0184 (-2.15%)
Day High 
0.867 
Prev. Close
0.8566 
1-M High
0.87 
Volume 
427.05K 
Bid
0.831
Ask
0.8429
Day Low
0.831 
Open
0.85325 
1-M Low
0.7301 
Market Cap 
109.23M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.84 
20-SMA 0.82 
50-SMA 0.85 
52-W High 1.51 
52-W Low 0.7301 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.35/-0.33
Enterprise Value
109.60M
Balance Sheet
Book Value Per Share
-0.05
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CLGNCollPlant Biotechnologies Ltd0.3879+0.0299+8.35%-- 
After Hours 0.3631 -0.0248 -6.39%
AIMAIM ImmunoTech Inc.0.226-0.0324-12.54%-- 
After Hours 0.245 +0.019 +8.41%
ROIVRoivant Sciences Ltd34.64-0.07-0.20%-- 
After Hours 34.45 -0.19 -0.55%
CVKDCadrenal Therapeutics Inc1.75+0.21+13.64%-- 
After Hours 1.69 -0.06 -3.43%
MRNAModerna140.34+2.35+1.70%-- 
After Hours 139.4 -0.94 -0.67%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.